Oclacitinib PF-03394197
Oclacitinib
CAS: 1208319-26-9
Molecular Formula: C15H23N5O2S
Oclacitinib PF-03394197 - Names and Identifiers
Oclacitinib PF-03394197 - Physico-chemical Properties
| Molecular Formula | C15H23N5O2S |
| Molar Mass | 337.44 |
| Density | 1.316±0.06 g/cm3(Predicted) |
| Melting Point | 226-228°C |
| Solubility | DMSO (Slightly), Methanol (Slightly, Sonicated) |
| Vapor Presure | 0Pa at 20-25℃ |
| Appearance | White or yellowish solid |
| Color | Off-White to Pale Beige |
| pKa | 11.59±0.40(Predicted) |
| Storage Condition | Refrigerator, Under inert atmosphere |
Oclacitinib PF-03394197 - Reference Information
| LogP | 1.38 at 35℃ and pH7 |
| Overview | olatinib (olatinib), a new type of JAK inhibitor, it also inhibits the function of jak1-dependent cytokines in some anti-allergic, inflammatory and pruritic responses. Studies have confirmed that experimental animals (dogs) in accordance with the 0.4-0.6mg/kg dose orally, twice a day, for the treatment of itching due to atopic dermatitis is safe and effective, and showed better efficacy than oral corticosteroids such as prednisolone. During the treatment period, administration of olatinib relieved the itch within 24 hours, with more than 70% of the experimental animals reducing greater than 50% of the itch response at Day 7. Currently, olatinib has been approved by the US FDA in 2013 for the control of pruritus and atopic dermatitis caused by allergic dermatitis in dogs. However, although the efficacy of olatinib on pet dog allergic skin disease is better, but its range of action is narrow, on the one hand, it has little effect on the cytokines that do not participate in the activation of JAK1, on the other hand, its effect on allergic reaction is only manifested in the inhibition of mast cell degranulation, that is, the release of allergic mediators, and can not fundamentally and directly block the binding of allergic mediators and related receptors, it can not fundamentally block the occurrence and development of allergic skin diseases. |
| Use | olatinib is a novel Janus kinase (JAK) inhibitor with anti-allergic cytokine activity. |
| olatinib was approved by the US FDA in to control pruritus and atopic dermatitis caused by allergic dermatitis in dogs. Olatinib (PF03394197) is a novel JAK and JAK1-dependentcytokines inhibitor with an IC50 of 10-99nm (jakfamy members) and 36-JAK1-dependentcytokines nm (), respectively. Olatinib is a very potent JAK1 inhibitor and also inhibits JAK1-dependentcytokines of its function in some anti-allergic, inflammatory and pruritic responses. It has little effect on cytokines that are not involved in the activation of JAK1. By the oral route, treatment of olatinib at 0.4-0.6mg/kg twice daily is safe and effective for the treatment of pruritus due to allergic dermatitis. During the treatment period, administration of olatinib relieved the itch within 24 hours, and in the experiment, more than 70% of the experimental animals (dogs) reduced the itch response by more than 50% at Day 7. |
Last Update：2024-04-09 02:00:14
Supplier List
Spot supply
Product Name: Oclacitinib Visit Supplier Webpage Request for quotationCAS: 1208319-26-9
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Oclacitinib Visit Supplier Webpage Request for quotation
CAS: 1208319-26-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1208319-26-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Oclacitinib Visit Supplier Webpage Request for quotationCAS: 1208319-26-9
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Oclacitinib Visit Supplier Webpage Request for quotation
CAS: 1208319-26-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1208319-26-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History